Covid vaccines: Will drug companies make bumper profits?

Firms that began work on vaccines for other diseases such as Zika and Sars had their fingers burnt. On the other hand, the market for flu’ jabs, which is worth several billion dollars a year, suggests that if Covid-19, like flu, is here to stay and requires annual booster jabs, then it could be profitable for the firms that come up with the most effective, and most cost-effective products.

Recent Posts

Tui to subsidise Covid tests for package holiday customers

However, he has concerns about the idea of making consumers shop around for Covid tests: "It's reducing competition in the industry - really, you need to have cheaper tests available to all consumers, not just if they book through a big holiday company."

read more

Plastic bag charge to double to 10p in all shops

Association of Convenience Stores chief executive, James Lowman, said: "We strongly welcome the inclusion of local shops and other small businesses into the successful plastic bag charging scheme, which not only helps the environment, but is also a great way for...

read more

Liberty steel owner in talks over £200m lifeline

GFG has been scrambling to raise new financing since its major financial backer Greensill Capital went bust in early March, which threw the future of Liberty Steel and its 3,000 workers into doubt. A further 2,000 people work at other GFG steel sites in the UK.

read more